Cargando…

Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism

Parkinson’s disease is a neurodegenerative ailment generated by the loss of dopamine in the basal ganglia, mainly in the striatum. The disease courses with increased striatal levels of acetylcholine, disrupting the balance among these modulatory transmitters. These modifications disturb the excitato...

Descripción completa

Detalles Bibliográficos
Autores principales: Padilla-Orozco, Montserrat, Duhne, Mariana, Fuentes-Serrano, Alejandra, Ortega, Aidán, Galarraga, Elvira, Bargas, José, Lara-González, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485566/
https://www.ncbi.nlm.nih.gov/pubmed/36147730
http://dx.doi.org/10.3389/fnsyn.2022.945816
_version_ 1784792097742651392
author Padilla-Orozco, Montserrat
Duhne, Mariana
Fuentes-Serrano, Alejandra
Ortega, Aidán
Galarraga, Elvira
Bargas, José
Lara-González, Esther
author_facet Padilla-Orozco, Montserrat
Duhne, Mariana
Fuentes-Serrano, Alejandra
Ortega, Aidán
Galarraga, Elvira
Bargas, José
Lara-González, Esther
author_sort Padilla-Orozco, Montserrat
collection PubMed
description Parkinson’s disease is a neurodegenerative ailment generated by the loss of dopamine in the basal ganglia, mainly in the striatum. The disease courses with increased striatal levels of acetylcholine, disrupting the balance among these modulatory transmitters. These modifications disturb the excitatory and inhibitory balance in the striatal circuitry, as reflected in the activity of projection striatal neurons. In addition, changes in the firing pattern of striatal tonically active interneurons during the disease, including cholinergic interneurons (CINs), are being searched. Dopamine-depleted striatal circuits exhibit pathological hyperactivity as compared to controls. One aim of this study was to show how striatal CINs contribute to this hyperactivity. A second aim was to show the contribution of extrinsic synaptic inputs to striatal CINs hyperactivity. Electrophysiological and calcium imaging recordings in Cre-mice allowed us to evaluate the activity of dozens of identified CINs with single-cell resolution in ex vivo brain slices. CINs show hyperactivity with bursts and silences in the dopamine-depleted striatum. We confirmed that the intrinsic differences between the activity of control and dopamine-depleted CINs are one source of their hyperactivity. We also show that a great part of this hyperactivity and firing pattern change is a product of extrinsic synaptic inputs, targeting CINs. Both glutamatergic and GABAergic inputs are essential to sustain hyperactivity. In addition, cholinergic transmission through nicotinic receptors also participates, suggesting that the joint activity of CINs drives the phenomenon; since striatal CINs express nicotinic receptors, not expressed in striatal projection neurons. Therefore, CINs hyperactivity is the result of changes in intrinsic properties and excitatory and inhibitory inputs, in addition to the modification of local circuitry due to cholinergic nicotinic transmission. We conclude that CINs are the main drivers of the pathological hyperactivity present in the striatum that is depleted of dopamine, and this is, in part, a result of extrinsic synaptic inputs. These results show that CINs may be a main therapeutic target to treat Parkinson’s disease by intervening in their synaptic inputs.
format Online
Article
Text
id pubmed-9485566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94855662022-09-21 Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism Padilla-Orozco, Montserrat Duhne, Mariana Fuentes-Serrano, Alejandra Ortega, Aidán Galarraga, Elvira Bargas, José Lara-González, Esther Front Synaptic Neurosci Neuroscience Parkinson’s disease is a neurodegenerative ailment generated by the loss of dopamine in the basal ganglia, mainly in the striatum. The disease courses with increased striatal levels of acetylcholine, disrupting the balance among these modulatory transmitters. These modifications disturb the excitatory and inhibitory balance in the striatal circuitry, as reflected in the activity of projection striatal neurons. In addition, changes in the firing pattern of striatal tonically active interneurons during the disease, including cholinergic interneurons (CINs), are being searched. Dopamine-depleted striatal circuits exhibit pathological hyperactivity as compared to controls. One aim of this study was to show how striatal CINs contribute to this hyperactivity. A second aim was to show the contribution of extrinsic synaptic inputs to striatal CINs hyperactivity. Electrophysiological and calcium imaging recordings in Cre-mice allowed us to evaluate the activity of dozens of identified CINs with single-cell resolution in ex vivo brain slices. CINs show hyperactivity with bursts and silences in the dopamine-depleted striatum. We confirmed that the intrinsic differences between the activity of control and dopamine-depleted CINs are one source of their hyperactivity. We also show that a great part of this hyperactivity and firing pattern change is a product of extrinsic synaptic inputs, targeting CINs. Both glutamatergic and GABAergic inputs are essential to sustain hyperactivity. In addition, cholinergic transmission through nicotinic receptors also participates, suggesting that the joint activity of CINs drives the phenomenon; since striatal CINs express nicotinic receptors, not expressed in striatal projection neurons. Therefore, CINs hyperactivity is the result of changes in intrinsic properties and excitatory and inhibitory inputs, in addition to the modification of local circuitry due to cholinergic nicotinic transmission. We conclude that CINs are the main drivers of the pathological hyperactivity present in the striatum that is depleted of dopamine, and this is, in part, a result of extrinsic synaptic inputs. These results show that CINs may be a main therapeutic target to treat Parkinson’s disease by intervening in their synaptic inputs. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485566/ /pubmed/36147730 http://dx.doi.org/10.3389/fnsyn.2022.945816 Text en Copyright © 2022 Padilla-Orozco, Duhne, Fuentes-Serrano, Ortega, Galarraga, Bargas and Lara-González. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Padilla-Orozco, Montserrat
Duhne, Mariana
Fuentes-Serrano, Alejandra
Ortega, Aidán
Galarraga, Elvira
Bargas, José
Lara-González, Esther
Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title_full Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title_fullStr Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title_full_unstemmed Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title_short Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
title_sort synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485566/
https://www.ncbi.nlm.nih.gov/pubmed/36147730
http://dx.doi.org/10.3389/fnsyn.2022.945816
work_keys_str_mv AT padillaorozcomontserrat synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT duhnemariana synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT fuentesserranoalejandra synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT ortegaaidan synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT galarragaelvira synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT bargasjose synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism
AT laragonzalezesther synapticdeterminantsofcholinergicinterneuronshyperactivityduringparkinsonism